Patents by Inventor Cornelis Van Berkel

Cornelis Van Berkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200345861
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Application
    Filed: July 21, 2020
    Publication date: November 5, 2020
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Patent number: 10799596
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: October 13, 2020
    Assignees: ADC THERAPEUTICS S.A., MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Publication number: 20200306385
    Abstract: The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.
    Type: Application
    Filed: May 26, 2020
    Publication date: October 1, 2020
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Patent number: 10780096
    Abstract: The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 22, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, John Hartley
  • Patent number: 10780181
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: September 22, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Patent number: 10751346
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 25, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Patent number: 10746745
    Abstract: The present invention relates to the identification of chemokine biomarkers predictive of future acute coronary syndromes including unstable angina pectoris (UAP). The present invention also identifies particular chemokines as potential therapeutic targets for intervention in cardiovascular diseases.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 18, 2020
    Assignees: Academisch Ziekenhuis Leiden, Universiteit Leiden
    Inventors: Ericus Anna Leonardus Biessen, Theodorus Josephus Cornelis Van Berkel, Adriaan Otto Kraaijeveld
  • Patent number: 10736903
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 11, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Patent number: 10722594
    Abstract: Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 28, 2020
    Assignees: ADC THERAPEUTICS S.A., MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 10695433
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 30, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Publication number: 20200129637
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 30, 2020
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • Publication number: 20200129638
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 30, 2020
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • Patent number: 10544223
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: January 28, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMTIED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • Publication number: 20190358342
    Abstract: A conjugate of formula (I): Ab-(DL)p wherein: Ab is an antibody, or an active fragment of an antibody; DL is (II).
    Type: Application
    Filed: February 8, 2018
    Publication date: November 28, 2019
    Inventor: Patricius Hendrikus Cornelis VAN BERKEL
  • Publication number: 20190352407
    Abstract: The present disclosure relates to humanized anti-Axl antibodies.
    Type: Application
    Filed: April 15, 2016
    Publication date: November 21, 2019
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, DAVID G. WILLIAMS
  • Publication number: 20190218291
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: November 21, 2018
    Publication date: July 18, 2019
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Jens WUERTHNER, John HARTLEY, Francesca ZAMMARCHI
  • Publication number: 20190015524
    Abstract: The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for in treating disorders characterized by the presence of CD25+ve cells.
    Type: Application
    Filed: November 25, 2015
    Publication date: January 17, 2019
    Applicants: MEDIMMUNE LIMITED, ADC THERAPEUTICS S.A.
    Inventors: JAY MARSHALL FEINGOLD, PATRICIUS HENDRIKUS CORNELIS VAN BERKEL
  • Publication number: 20180303953
    Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds AXL, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 25, 2018
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Publication number: 20180250417
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Application
    Filed: February 15, 2018
    Publication date: September 6, 2018
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Publication number: 20180193480
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Application
    Filed: March 5, 2018
    Publication date: July 12, 2018
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD